Repligen Co. (NASDAQ:RGEN) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Repligen Co. (NASDAQ:RGEN) have been given an average rating of “Moderate Buy” by the thirteen brokerages that are covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $185.20.

A number of equities analysts have recently commented on the stock. Canaccord Genuity Group started coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price on the stock. Royal Bank of Canada restated an “outperform” rating and set a $205.00 price objective on shares of Repligen in a report on Thursday, September 26th. Wolfe Research started coverage on Repligen in a report on Thursday, November 14th. They issued a “peer perform” rating for the company. Canaccord Genuity Group began coverage on Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. Finally, StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research note on Friday, January 3rd.

Institutional Investors Weigh In On Repligen

A number of hedge funds and other institutional investors have recently bought and sold shares of RGEN. Ballentine Partners LLC increased its position in shares of Repligen by 4.0% during the fourth quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company’s stock worth $270,000 after purchasing an additional 72 shares in the last quarter. Toronto Dominion Bank grew its stake in Repligen by 1.5% during the 2nd quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company’s stock worth $656,000 after buying an additional 75 shares during the last quarter. DekaBank Deutsche Girozentrale increased its position in Repligen by 1.1% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company’s stock valued at $982,000 after buying an additional 89 shares in the last quarter. MML Investors Services LLC raised its stake in Repligen by 2.7% in the third quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company’s stock valued at $503,000 after buying an additional 89 shares during the last quarter. Finally, GAMMA Investing LLC boosted its holdings in Repligen by 15.2% in the fourth quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock worth $98,000 after acquiring an additional 90 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Price Performance

Shares of RGEN stock opened at $160.51 on Friday. The stock has a 50 day moving average price of $148.36 and a 200 day moving average price of $144.64. Repligen has a 52-week low of $113.50 and a 52-week high of $211.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.09. The business had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The business’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same period last year, the company earned $0.23 earnings per share. On average, research analysts forecast that Repligen will post 1.54 EPS for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.